
The AiDAPT trial assessed hybrid closed loop (HCL) insulin therapy in postpartum type 1 diabetes. Among 57 participants, HCL increased time in range (72% vs. 54%, difference 15%, 95% CI 7 to 22) and reduced hyperglycemia without increasing hypoglycemia. No safety concerns were identified, supporting HCL as an effective postpartum management option.
Like
Save
Share